GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
GH Research reported a net loss of $19.0 million, or $0.31 per share, for the first quarter of 2026, compared to a loss of $10.8 million, or $0.19 per share, in the same period last year. The company's cash, cash equivalents, and marketable securities decreased to $267.3 million as of March 31, 2026, from $280.7 million as of December 31, 2025. Research and development expenses increased to $12.4 million in Q1 2026 from $7.9 million in Q1 2025, primarily due to higher technical and clinical development costs.
Key figures
- Eps Beat
- 0
- Revenue
- 0
- Revenue Yoy
- 0
- Net loss
- 18967000
- Cash position
- 267300000
- G and a expenses
- 6370000
- R and d expenses
- 12379000
- Total comprehensive loss
- 18229000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.